Neuroprotective Drug Riluzole Improves Efficacy of Surgical Decompression in Cervical Myelopathy
Fehlings lab research on the blogosphere!
The Fehlings team were delighted to have our publication regarding Riluzole and its protective effects on ischemia-reperfusion injury after surgical decompression for degenerative cervical myelopathy (DCM) accepted to Science Translational Medicine and published last year [Science Translational Medicine]. DCM is a common cause of spinal cord impairment in the elderly. This paper links results from human research, showing that some patients experience deterioration after surgery for degenerative cervical myelopathy, with evidence from an animal model suggesting a mechanism for this deterioration (ischemia-reperfusion injury), in addition to reporting findings from this animal model that Riluzole can protect against this effect. Understanding this mechanism gives further support to the ongoing trial of this drug in DCM [CSM-Protect trial – clinicaltrials.gov]
We were further delighted to partner with External Diffusion, earlier this year to have this research made a feature in a blog post to reach an even wider and less specalised audience than the original scientific paper. Read all about this here [http://www.externaldiffusion.com/]
by Madeleine O’Higgins, Communications Specialist in Fehlings Lab